First patients enrolled in Medtronic CoreValve Evolut R trial in low-risk aortic stenosis patients

250

Medtronic_CoreValve_Evolut_main_Main

The first patients have been enrolled in the expanded indication trial for the CoreValve Evolut R next-generation, recapturable, self-expanding transcatheter aortic valve replacement (TAVR) system from Medtronic.

The patients were enrolled at PinnacleHealth CardioVascular Institute in Harrisburg, USA. The heart team led by Mubashir Mumtaz, chief of cardiothoracic surgery and Hemal Gada, medical director of structural heart at PinnacleHealth, performed the first procedures in the trial.

“Our team of cardiologists and cardiovascular surgeons is pleased to be involved in this next phase of clinical investigation,” says Mumtaz. “It is invigorating to… help heart teams understand the potential benefits of TAVR in a broader patient population.”

This clinical trial will include 1,200 patients with severe aortic stenosis who have a less than 3% risk of operative mortality, as determined by a heart team. The trial will enrol low-risk patients from up to 80 clinical sites with 1:1 randomisation to receive the Evolut R System or undergo open-heart surgery (surgical aortic valve replacement or SAVR). The investigational device exemption (IDE) is designed as an adaptive trial with a primary endpoint of all-cause mortality or disabling stroke. The trial has a two-year endpoint and allows for a one-year analysis for early US Food and Drug Administration (FDA) submission. Additionally, the trial will include a sub-study of leaflet mobility in 400 patients.

The Evolut R system is designed to increase conformability and sealing at the annulus, while maintaining supra-annular valve positioning for improved blood flow and haemodynamic performance. The valve is delivered through the EnVeo R Delivery Catheter System, which features an InLine Sheath that provides the lowest profile on the market (14Fr equivalent, less than 1/5 inch). The low profile enables treatment of patients with vessels down to 5mm through the preferred transfemoral access route, and may minimize the risk of major vascular complications in some patients.

The CoreValve Evolut R transcatheter valve and the CoreValve EnVeo R Delivery Catheter System were FDA-approved for commercial use in the United States in June 2015. It is also available in Europe and other countries that recognise the CE mark.